BioLargo Inc
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per - and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediati… Read more
BioLargo Inc (BLGO) - Net Assets
Latest net assets as of September 2025: $3.21 Million USD
Based on the latest financial reports, BioLargo Inc (BLGO) has net assets worth $3.21 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.13 Million) and total liabilities ($5.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.21 Million |
| % of Total Assets | 35.21% |
| Annual Growth Rate | -0.37% |
| 5-Year Change | N/A |
| 10-Year Change | 430.59% |
| Growth Volatility | 124.11 |
BioLargo Inc - Net Assets Trend (2000–2024)
This chart illustrates how BioLargo Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioLargo Inc (2000–2024)
The table below shows the annual net assets of BioLargo Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.06 Million | +44.12% |
| 2023-12-31 | $4.20 Million | +108.95% |
| 2022-12-31 | $2.01 Million | +115.54% |
| 2021-12-31 | $933.00K | +497.02% |
| 2020-12-31 | $-235.00K | +89.22% |
| 2019-12-31 | $-2.18 Million | -94.12% |
| 2018-12-31 | $-1.12 Million | +67.06% |
| 2017-12-31 | $-3.41 Million | -342.69% |
| 2016-12-31 | $-770.20K | -167.48% |
| 2015-12-31 | $1.14 Million | +391.17% |
| 2014-12-31 | $-392.00K | +30.62% |
| 2013-12-31 | $-565.00K | -95.50% |
| 2012-12-31 | $-289.00K | +80.96% |
| 2011-12-31 | $-1.52 Million | +41.46% |
| 2010-12-31 | $-2.59 Million | +32.88% |
| 2009-12-31 | $-3.86 Million | -152.53% |
| 2008-12-31 | $7.35 Million | -18.61% |
| 2007-12-31 | $9.04 Million | +269.56% |
| 2006-12-31 | $-5.33 Million | -11.23% |
| 2005-12-31 | $-4.79 Million | -63.85% |
| 2003-12-31 | $-2.92 Million | -248.20% |
| 2002-12-31 | $1.97 Million | +63.73% |
| 2001-12-31 | $1.21 Million | -81.80% |
| 2000-12-31 | $6.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioLargo Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14950000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $158.35 Million | 1789.07% |
| Total Equity | $8.85 Million | 100.00% |
BioLargo Inc Competitors by Market Cap
The table below lists competitors of BioLargo Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Midas Minerals Ltd
AU:MM1
|
$51.89 Million |
|
Migdal Insurance
TA:MGDL
|
$51.90 Million |
|
Kamux Suomi Oy
HE:KAMUX
|
$51.91 Million |
|
CVC Technologies
TWO:4744
|
$51.91 Million |
|
NIPPON AQUA CO. LTD.
F:N3A
|
$51.87 Million |
|
Kronos Bio Inc
NASDAQ:KRON
|
$51.83 Million |
|
Meta Biomed Co. Ltd
KQ:059210
|
$51.83 Million |
|
Lavras Gold Corp.
OTCQX:LGCFF
|
$51.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioLargo Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,844,000 to 8,851,000, a change of 2,007,000 (29.3%).
- Net loss of 2,402,000 reduced equity.
- New share issuances of 2,649,000 increased equity.
- Other factors increased equity by 1,760,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.40 Million | -27.14% |
| Share Issuances | $2.65 Million | +29.93% |
| Other Changes | $1.76 Million | +19.88% |
| Total Change | $- | 29.32% |
Book Value vs Market Value Analysis
This analysis compares BioLargo Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.53x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $0.28 | x |
| 2016-12-31 | $0.00 | $0.28 | x |
| 2017-12-31 | $-0.04 | $0.28 | x |
| 2018-12-31 | $-0.01 | $0.28 | x |
| 2019-12-31 | $-0.01 | $0.28 | x |
| 2020-12-31 | $0.02 | $0.28 | x |
| 2021-12-31 | $0.02 | $0.28 | x |
| 2022-12-31 | $0.02 | $0.28 | x |
| 2023-12-31 | $0.02 | $0.28 | x |
| 2024-12-31 | $0.03 | $0.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioLargo Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.51%
- • Asset Turnover: 1.69x
- • Equity Multiplier: 1.19x
- Recent ROE (-27.14%) is above the historical average (-179.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -3296.53% | 0.43x | 0.00x | $-3.65 Million |
| 2015 | -1437.19% | -3962.92% | 0.07x | 5.43x | $-5.09 Million |
| 2016 | 0.00% | -2788.89% | 0.13x | 0.00x | $-7.71 Million |
| 2017 | 0.00% | -1766.19% | 0.35x | 0.00x | $-8.71 Million |
| 2018 | 0.00% | -749.34% | 0.43x | 0.00x | $-10.07 Million |
| 2019 | 0.00% | -574.42% | 0.51x | 0.00x | $-10.47 Million |
| 2020 | -218.56% | -346.71% | 0.49x | 1.28x | $-8.82 Million |
| 2021 | -152.16% | -279.73% | 0.84x | 0.65x | $-7.55 Million |
| 2022 | -91.70% | -76.02% | 1.21x | 1.00x | $-4.96 Million |
| 2023 | -51.20% | -28.65% | 1.49x | 1.20x | $-4.19 Million |
| 2024 | -27.14% | -13.51% | 1.69x | 1.19x | $-3.29 Million |
Industry Comparison
This section compares BioLargo Inc's net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $4,530,711,947
- Average return on equity (ROE) among peers: -6.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioLargo Inc (BLGO) | $3.21 Million | 0.00% | 1.84x | $51.87 Million |
| Synalloy Corporation (ACNT) | $102.48 Million | 12.78% | 1.23x | $94.68 Million |
| Advance ZincTek Limited (ADVNF) | $35.28 Million | 4.71% | 0.11x | $5.02 Million |
| AdvanSix Inc (ASIX) | $738.18 Million | 23.29% | 1.03x | $435.20 Million |
| ASP Isotopes Inc. Common Stock (ASPI) | $51.17 Million | -63.19% | 0.84x | $409.15 Million |
| Braskem SA Class A (BAK) | $2.54 Billion | -64.23% | 1.22x | $936.09 Million |
| Bachem Holding AG (BCHMF) | $447.82 Million | 12.10% | 0.45x | $1.98 Billion |
| BASF SE NA O.N. (BFFAF) | $34.76 Billion | 17.49% | 1.27x | $47.09 Billion |
| Black Swan Graphene Inc. (BSWGF) | $14.00 Million | -13.86% | 0.01x | $10.07 Million |
| Celanese Corporation (CE) | $2.10 Billion | 8.02% | 2.06x | $6.44 Billion |